Expanded Access: Autologous HB-adMSCs for the Treatment of Spinal Cord Injury
Spinal Cord Injury at C5-C7 Level
Enrolment not recorded · Results not recorded
Loading the evidence…
Biologic
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Spinal Cord Injury at C5-C7 Level
Enrolment not recorded · Results not recorded
Urinary Incontinence, Stress
Enrolment: 50 · Results not recorded
Diabetic Foot Ulcer
Enrolment: 64 · Results not recorded
Ileal Pouch · Crohn Disease
Enrolment: 24 · Results not recorded
Parkinson's Disease
Enrolment: 20 · Results not recorded
Pulmonary Hypertension
Enrolment: 60 · Results not recorded
Leg Length Inequality
Enrolment: 6 · Results not recorded
Erectile Dysfunction · Cardiac Disease
Enrolment: 0 · Results not recorded
Osteoarthritis, Knee
Enrolment: 15 · Results not recorded
Parkinson Disease
Enrolment not recorded · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Methotrexate 14 mg/kg given orally as a single dose per week for 2 weeks
Both bone marrow-derived and adipose-derived mesenchymal stem cells alleviated methotrexate-induced oxidative stress, biochemical derangement and histological damage in kidney and liver, to a greater extent than dexamethasone.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.